GlassScriptPhysician profile
Edward William Leahey
NPI 1770584690
$81,268.41
in general payments reported to CMS, 2019-2025
54 companies · $1,134 in 2025
The $1,134 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $67K · 2020: $2,400 · 2021: $2,916 · 2022: $2,908 · 2023: $2,707 · 2024: $2,052 · 2025: $1,134.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,893.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,893.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $62,540.79 | 2019 | |
| Abbott Laboratories | $6,203.17 | 2019-2025 | Gallant, Accent, Cardiomems |
| Amgen INC. | $1,275.48 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,150.05 | 2019-2025 | |
| Shockwave Medical, INC | $934.32 | 2021-2025 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter, Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Pfizer INC. | $917.88 | 2019-2024 | |
| Amarin Pharma, INC. | $828.92 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $807.33 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $746.33 | 2021-2025 | Verquvo, Capvaxive |
| Boston Scientific Corporation | $650.49 | 2019-2025 | Bodyguardian, Lux-Dx Insertable Cardiac Monitor, Watchman Access System |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $616.99 | 2019-2025 | Lifevest |
| Esperion Therapeutics, INC. | $575.64 | 2020-2025 | Nexletol |
| Impulse Dynamics (USA) INC. | $543.70 | 2022-2024 | Optimizer, Optimizer |
| E.R. Squibb & Sons, L.L.C. | $498.55 | 2019-2024 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $407.63 | 2019-2024 | Farxiga, Brilinta |
Show all 54 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Leahey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.